Related Experiment Video
Updated: Mar 7, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.3K
Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients
Julia D J Thomas1, Abhishek Dattani1,2, Filip Zemrak2
1Centre for Endocrinology, WHRI, Barts & the London School of Medicine and Dentistry, Queen Mary University of London.
Summary
Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) improved cardiac function in acromegaly patients with hypertension. These medications may offer cardiac benefits in acromegaly, warranting further investigation.
Area of Science:
- Cardiology
- Endocrinology
Background:
- Acromegaly is linked to a specific cardiomyopathy with unclear pathogenesis.
- The renin-angiotensin system blockade (ACEi/ARBs) improves cardiac outcomes post-myocardial infarction and in heart failure.
Purpose of the Study:
- To compare cardiac indices in acromegaly patients with varying hypertension status and medication use.
- To investigate the potential cardiac benefits of ACEi/ARBs in acromegaly.
Main Methods:
- Cardiac magnetic imaging was used to assess cardiac indices.
- Patients were categorized into three groups: active acromegaly without hypertension, hypertension without ACEi/ARBs, and hypertension with ACEi/ARBs.
Main Results:
- Patients on ACEi/ARBs exhibited significantly lower end-diastolic volume index (EDVi) and end-systolic volume index (ESVi) compared to the other groups.
- Acromegaly patients with hypertension on ACEi/ARBs showed improved cardiac indices compared to those not on these medications.
Conclusions:
- ACEi/ARBs appear to improve cardiac indices in acromegaly patients with hypertension.
- Further research is needed to confirm the beneficial cardiac effects of ACEi/ARBs in acromegaly, even without overt hypertension.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
01:22Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
01:17Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K